CD20-CD19 compound CAR-T cells

{
  "id": "MLC-T-ONC-012387",
  "term": "CD20-CD19 compound CAR-T cells",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of T lymphocytes transduced with a lentiviral vector expressing a compound chimeric antigen receptor (cCAR) containing two distinct units of CARs, one specific for the tumor-associated antigen (TAA) cluster of differentiation 20 (CD20) and one specific for the TAA CD19, with potential immunomodulating and antineoplastic activities. Upon administration, the CD20-CD19 cCAR-T cells specifically and simultaneously target and bind to tumor cells expressing CD20 and/or CD19. This induces selective toxicity in tumor cells that express CD20 and/or CD19. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting two different antigens may improve coverage and protect against antigen escape and relapse as it is less likely for tumor cells to lose both antigens.",
  "synonyms": [
    "CD20-CD19 cCAR T cells",
    "CD20-CD19 cCAR-T cells",
    "CD19/CD20-expressing compound CAR-T cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/cd20-cd19-compound-car-t-cells/"
}